Rapcabtagene autoleucel is a type of cell therapy where a patient’s own T cells (a type of immune cell) are modified in a laboratory. These modified cells are designed to target specific cells in the body that are involved in systemic sclerosis, a serious autoimmune condition affecting the skin and internal organs. The therapy is given as a single infusion into the bloodstream.

Rituximab is an antibody medication that works by targeting and reducing certain types of B cells (immune cells) in the body. It is commonly used to treat various autoimmune conditions and certain types of cancer. The medication is given through an infusion into the bloodstream and works by modifying the immune system’s response.

Diffuse cutaneous systemic sclerosis (dcSSc) – A rare autoimmune disease that causes hardening and tightening of the skin and connective tissues throughout the body. The condition begins with inflammation and swelling of the skin, which later leads to excessive collagen production causing skin thickening. It affects large areas of the skin, particularly on the trunk, face, and limbs. The disease typically progresses relatively quickly over the first few years after onset. Internal organs may also be affected as the condition develops. The term “diffuse” refers to the widespread nature of skin involvement, distinguishing it from other forms of systemic sclerosis.